GSK (GLAXF) Cyclically Adjusted PB Ratio: (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLAXF GSK PLC GLAXF
69 GF Score
Price $26.20
GF Value $21.81
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is GSK Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GSK  (OTCPK:GLAXF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GSK Cyclically Adjusted PB Ratio Related Terms


GSK Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for GSK's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Cyclically Adjusted PB Ratio Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.76 6.76 6.28 5.29 6.53

GSK Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.23 5.79 6.53 7.12 0.00

GLAXF vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PB Ratio falls into.


GLAXF
69GF Score
GSK PLC GLAXF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GSK's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, GSK's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.792/142.1000*142.1000
=5.792

Current CPI (Jun. 2026) = 142.1000.

GSK Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.046 101.500 0.064
201612 0.357 102.200 0.496
201703 0.541 102.700 0.749
201706 0.264 103.500 0.362
201709 0.441 104.300 0.601
201712 -0.023 105.000 -0.031
201803 -0.025 105.100 -0.034
201806 1.233 105.900 1.654
201809 1.487 106.600 1.982
201812 1.205 107.100 1.599
201903 1.337 107.000 1.776
201906 1.148 107.900 1.512
201909 3.651 108.400 4.786
201912 3.745 108.500 4.905
202003 4.071 108.600 5.327
202006 4.238 108.800 5.535
202009 4.610 109.200 5.999
202012 4.872 109.400 6.328
202103 5.123 109.700 6.636
202106 5.358 111.400 6.835
202109 5.264 112.400 6.655
202112 4.973 114.700 6.161
202203 5.298 116.500 6.462
202206 4.958 120.500 5.847
202209 2.548 122.300 2.961
202212 3.153 125.300 3.576
202303 3.540 126.800 3.967
202306 3.913 129.400 4.297
202309 4.007 130.100 4.377
202312 4.165 130.500 4.535
202403 4.312 131.600 4.656
202406 4.483 133.000 4.790
202409 4.541 133.500 4.834
202412 4.235 135.100 4.454
202503 4.478 136.100 4.675
202506 4.960 138.400 5.093
202509 5.420 138.900 5.545
202512 5.464 139.900 5.550
202603 5.921 140.800 5.976
202606 5.792 142.100 5.792

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $26.20 is trading 20.1% above its estimated GF Value™ of $21.81. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $21.81 vs. price of $26.20 (20.1% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score

Get the complete analysis for GLAXF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.20
Price
$21.81
GF Value